Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Ran-Fentanyl Matrix Patch (02330105), Co Fentanyl Matrix Patch (02386844). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

FENTANYL TRANSDERMAL SYSTEM

8 Limited Use · 14 not a benefit

Other products in the same Health Canada class (N02A) — coverage varies; not interchangeable

  • Acetaminophen + caffeine + codeine (Teva-Lenoltec No.2): general benefit, Not a benefit
  • Acetaminophen + codeine (PMS-Acetaminophen With Codeine): general benefit, Not a benefit
  • Hydromorphone (Hydromorph Contin): general benefit, Not a benefit
  • Morphine (M-Eslon): general benefit, Not a benefit
  • Acetaminophen + oxycodone (Teva-Oxycocet): general benefit, Not a benefit
  • Acetylsalicylic acid + oxycodone (Ratio-Oxycodan): general benefit, Not a benefit

4 more in the class list below

Sandoz Fentanyl Patch · DIN 02327112 · 12mcg/hr · Trans Patch

Limited Use — Reason for Use code 511 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 511 required
Write on scriptLU code 511 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 511
Reason for Use code 511 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long-acting opioid will be subject to verification at the time of dispensing. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Sandoz Fentanyl Patch · DIN 02327112 Manufacturer: Sandoz Canada Inc.; listing date 2010-03-02 Health Canada: Marketed since 2010-11-01 · brand SANDOZ FENTANYL PATCH · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 12 MCG/HOUR · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Sandoz Fentanyl Patch: Formulary list price $3.3200/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.3200 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81243 · Verify on the e-Formulary ↗ (DIN 02327112)

Source record
DIN 02327112: Sandoz Fentanyl Patch Raw flags: sec12=Y, sec3=Y Item: 280808169; group id 402; item number 0961; lccId 00402; manufacturer id SDZ Source form: Trans Patch; strength: 12mcg/hr Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.3200; ministry $3.3200 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02327112 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81243
Interchangeable products
Duragesic 12 · DIN 02280345 · not recorded Teva-Fentanyl · DIN 02311925 · $3.3200
Shortage status: resolved shortage (ended 2025-04-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02327112
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Fentanyl · DIN 02311925 · 12mcg/hr · Trans Patch

Limited Use — Reason for Use code 511 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 511 required
Write on scriptLU code 511 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 511
Reason for Use code 511 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long-acting opioid will be subject to verification at the time of dispensing. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Teva-Fentanyl · DIN 02311925 Manufacturer: Teva Canada Limited; listing date 2008-12-23 Health Canada: Marketed since 2012-12-21 · brand TEVA-FENTANYL · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 12 MCG/HOUR · company Teva canada limited · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Teva-Fentanyl: Formulary list price $3.3200/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.3200 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79746 · Verify on the e-Formulary ↗ (DIN 02311925)

Source record
DIN 02311925: Teva-Fentanyl Raw flags: sec12=Y, sec3=Y Item: 280808169; group id 402; item number 0961; lccId 00402; manufacturer id TEV Source form: Trans Patch; strength: 12mcg/hr Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.3200; ministry $3.3200 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02311925 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79746
Interchangeable products
Duragesic 12 · DIN 02280345 · not recorded Sandoz Fentanyl Patch · DIN 02327112 · $3.3200
Shortage status: resolved shortage (ended 2025-05-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02311925
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Fentanyl Patch · DIN 02327120 · 25mcg/hr · Trans Patch

Limited Use — Reason for Use code 511 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 511 required
Write on scriptLU code 511 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 511
Reason for Use code 511 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long-acting opioid will be subject to verification at the time of dispensing. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Sandoz Fentanyl Patch · DIN 02327120 Manufacturer: Sandoz Canada Inc.; listing date 2010-03-02 Health Canada: Marketed since 2010-11-01 · brand SANDOZ FENTANYL PATCH · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 25 MCG/HOUR · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Sandoz Fentanyl Patch: Formulary list price $8.5600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.5600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81244 · Verify on the e-Formulary ↗ (DIN 02327120)

Source record
DIN 02327120: Sandoz Fentanyl Patch Raw flags: sec12=Y, sec3=Y Item: 280808079; group id 404; item number 0963; lccId 00067; manufacturer id SDZ Source form: Trans Patch; strength: 25mcg/hr Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $8.5600; ministry $8.5600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02327120 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81244
Interchangeable products
Duragesic · DIN 02275813 · not recorded Duragesic 25 · DIN 01937383 · not recorded Teva-Fentanyl · DIN 02282941 · $8.5600
Shortage status: resolved shortage (ended 2022-02-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02327120
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Fentanyl · DIN 02282941 · 25mcg/hr · Trans Patch

Limited Use — Reason for Use code 511 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 511 required
Write on scriptLU code 511 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 511
Reason for Use code 511 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long-acting opioid will be subject to verification at the time of dispensing. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Teva-Fentanyl · DIN 02282941 Manufacturer: Teva Canada Limited; listing date 2007-01-02 Health Canada: Marketed since 2012-12-21 · brand TEVA-FENTANYL · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 25 MCG/HOUR · company Teva canada limited · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Teva-Fentanyl: Formulary list price $8.5600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.5600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76857 · Verify on the e-Formulary ↗ (DIN 02282941)

Source record
DIN 02282941: Teva-Fentanyl Raw flags: sec12=Y, sec3=Y Item: 280808079; group id 404; item number 0963; lccId 00067; manufacturer id TEV Source form: Trans Patch; strength: 25mcg/hr Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $8.5600; ministry $8.5600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02282941 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76857
Interchangeable products
Duragesic · DIN 02275813 · not recorded Duragesic 25 · DIN 01937383 · not recorded Sandoz Fentanyl Patch · DIN 02327120 · $8.5600
Shortage status: resolved shortage (ended 2024-05-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02282941
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Fentanyl Patch · DIN 02327147 · 50mcg/hr · Trans Patch

Limited Use — Reason for Use code 511 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 511 required
Write on scriptLU code 511 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 511
Reason for Use code 511 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long-acting opioid will be subject to verification at the time of dispensing. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Sandoz Fentanyl Patch · DIN 02327147 Manufacturer: Sandoz Canada Inc.; listing date 2010-03-02 Health Canada: Marketed since 2010-11-01 · brand SANDOZ FENTANYL PATCH · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 50 MCG/HOUR · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Sandoz Fentanyl Patch: Formulary list price $16.1100/unit (unit not stated in source; not the patient's cost)

Ministry pays: $16.1100 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81246 · Verify on the e-Formulary ↗ (DIN 02327147)

Source record
DIN 02327147: Sandoz Fentanyl Patch Raw flags: sec12=Y, sec3=Y Item: 280808080; group id 404; item number 0964; lccId 00067; manufacturer id SDZ Source form: Trans Patch; strength: 50mcg/hr Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $16.1100; ministry $16.1100 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02327147 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81246
Interchangeable products
Duragesic · DIN 02275821 · not recorded Duragesic 50 · DIN 01937391 · not recorded Teva-Fentanyl · DIN 02282968 · $16.1100
Shortage status: resolved shortage (ended 2023-01-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02327147
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Fentanyl · DIN 02282968 · 50mcg/hr · Trans Patch

Limited Use — Reason for Use code 511 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 511 required
Write on scriptLU code 511 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 511
Reason for Use code 511 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long-acting opioid will be subject to verification at the time of dispensing. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Teva-Fentanyl · DIN 02282968 Manufacturer: Teva Canada Limited; listing date 2007-01-02 Health Canada: Marketed since 2012-12-21 · brand TEVA-FENTANYL · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 50 MCG/HOUR · company Teva canada limited · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Teva-Fentanyl: Formulary list price $16.1100/unit (unit not stated in source; not the patient's cost)

Ministry pays: $16.1100 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76858 · Verify on the e-Formulary ↗ (DIN 02282968)

Source record
DIN 02282968: Teva-Fentanyl Raw flags: sec12=Y, sec3=Y Item: 280808080; group id 404; item number 0964; lccId 00067; manufacturer id TEV Source form: Trans Patch; strength: 50mcg/hr Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $16.1100; ministry $16.1100 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02282968 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76858
Interchangeable products
Duragesic · DIN 02275821 · not recorded Duragesic 50 · DIN 01937391 · not recorded Sandoz Fentanyl Patch · DIN 02327147 · $16.1100
Shortage status: resolved shortage (ended 2025-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02282968
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Fentanyl Patch · DIN 02327155 · 75mcg/hr · Trans Patch

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Fentanyl Patch · DIN 02327155 Manufacturer: Sandoz Canada Inc.; listing date 2010-03-02 Health Canada: Marketed since 2010-11-01 · brand SANDOZ FENTANYL PATCH · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 75 MCG/HOUR · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81247 · Verify on the e-Formulary ↗ (DIN 02327155)

Source record
DIN 02327155: Sandoz Fentanyl Patch Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280808081; group id 405; item number 0965; lccId None; manufacturer id SDZ Source form: Trans Patch; strength: 75mcg/hr Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $22.6500; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02327155 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81247
Interchangeable products
Duragesic · DIN 02275848 · not recorded Duragesic 75 · DIN 01937405 · not recorded Teva-Fentanyl · DIN 02282976 · not recorded
Shortage status: resolved shortage (ended 2022-01-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02327155
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Fentanyl · DIN 02282976 · 75mcg/hr · Trans Patch

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Fentanyl · DIN 02282976 Manufacturer: Teva Canada Limited; listing date 2007-01-02 Health Canada: Marketed since 2012-12-21 · brand TEVA-FENTANYL · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 75 MCG/HOUR · company Teva canada limited · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76859 · Verify on the e-Formulary ↗ (DIN 02282976)

Source record
DIN 02282976: Teva-Fentanyl Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280808081; group id 405; item number 0965; lccId None; manufacturer id TEV Source form: Trans Patch; strength: 75mcg/hr Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $22.6500; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02282976 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76859
Interchangeable products
Duragesic · DIN 02275848 · not recorded Duragesic 75 · DIN 01937405 · not recorded Sandoz Fentanyl Patch · DIN 02327155 · not recorded
Shortage status: resolved shortage (ended 2025-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02282976
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Fentanyl Patch · DIN 02327163 · 100mcg/hr · Trans Patch

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Fentanyl Patch · DIN 02327163 Manufacturer: Sandoz Canada Inc.; listing date 2010-03-02 Health Canada: Marketed since 2010-11-01 · brand SANDOZ FENTANYL PATCH · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 100 MCG/HOUR · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81248 · Verify on the e-Formulary ↗ (DIN 02327163)

Source record
DIN 02327163: Sandoz Fentanyl Patch Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280808082; group id 405; item number 0966; lccId None; manufacturer id SDZ Source form: Trans Patch; strength: 100mcg/hr Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $28.1950; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02327163 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81248
Interchangeable products
Duragesic · DIN 02275856 · not recorded Duragesic 100 · DIN 01937413 · not recorded Teva-Fentanyl · DIN 02282984 · not recorded
Shortage status: resolved shortage (ended 2023-01-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02327163
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Fentanyl · DIN 02282984 · 100mcg/hr · Trans Patch

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Fentanyl · DIN 02282984 Manufacturer: Teva Canada Limited; listing date 2007-01-02 Health Canada: Marketed since 2012-12-21 · brand TEVA-FENTANYL · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 100 MCG/HOUR · company Teva canada limited · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76860 · Verify on the e-Formulary ↗ (DIN 02282984)

Source record
DIN 02282984: Teva-Fentanyl Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280808082; group id 405; item number 0966; lccId None; manufacturer id TEV Source form: Trans Patch; strength: 100mcg/hr Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $28.1950; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02282984 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76860
Interchangeable products
Duragesic · DIN 02275856 · not recorded Duragesic 100 · DIN 01937413 · not recorded Sandoz Fentanyl Patch · DIN 02327163 · not recorded
Shortage status: resolved shortage (ended 2026-06-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02282984
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Fentanyl Patch · PIN 09858348 · 12mcg/hr · Trans Patch

Limited Use — Reason for Use code 689 requiredOntario PIN; no Health Canada record under this code
StatusLimited Use — Reason for Use code 689 required
Write on scriptLU code 689 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 689
Reason for Use code 689 For the treatment of chronic pain in patients who have been stabilized on fentanyl and require the use of fentanyl 12mcg/hr patches for dose adjustment up or down to the lowest optimal opioid dose. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Sandoz Fentanyl Patch · DIN 09858348 Manufacturer: Sandoz Canada Inc.; listing date 2024-09-27 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Sandoz Fentanyl Patch: Formulary list price $3.3200/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.3200 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858348)

Source record
DIN 09858348: Sandoz Fentanyl Patch Raw flags: sec12=Y, sec3=Y Item: 280808469; group id 403; item number 0962; lccId 00403; manufacturer id SDZ Source form: Trans Patch; strength: 12mcg/hr Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.3200; ministry $3.3200 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09858348 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Duragesic 12 · DIN 09858350 · not recorded Teva-Fentanyl · DIN 09858349 · $3.3200
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09858348
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Fentanyl · PIN 09858349 · 12mcg/hr · Trans Patch

Limited Use — Reason for Use code 689 requiredOntario PIN; no Health Canada record under this code
StatusLimited Use — Reason for Use code 689 required
Write on scriptLU code 689 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 689
Reason for Use code 689 For the treatment of chronic pain in patients who have been stabilized on fentanyl and require the use of fentanyl 12mcg/hr patches for dose adjustment up or down to the lowest optimal opioid dose. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Teva-Fentanyl · DIN 09858349 Manufacturer: Teva Canada Limited; listing date 2024-09-27 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Teva-Fentanyl: Formulary list price $3.3200/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.3200 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858349)

Source record
DIN 09858349: Teva-Fentanyl Raw flags: sec12=Y, sec3=Y Item: 280808469; group id 403; item number 0962; lccId 00403; manufacturer id TEV Source form: Trans Patch; strength: 12mcg/hr Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.3200; ministry $3.3200 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09858349 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Duragesic 12 · DIN 09858350 · not recorded Sandoz Fentanyl Patch · DIN 09858348 · $3.3200
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09858349
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Duragesic 12 · PIN 09858350 · 12mcg/hr · Trans Patch

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 689
Reason for Use code 689 For the treatment of chronic pain in patients who have been stabilized on fentanyl and require the use of fentanyl 12mcg/hr patches for dose adjustment up or down to the lowest optimal opioid dose. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Duragesic 12 · DIN 09858350 Manufacturer: Janssen-Ortho Inc.; listing date 2024-09-27 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Duragesic 12: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858350)

Source record
DIN 09858350: Duragesic 12 Raw flags: notABenefit=Y, sec3=Y Item: 280808469; group id 403; item number 0962; lccId 00403; manufacturer id JNO Source form: Trans Patch; strength: 12mcg/hr Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09858350 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Sandoz Fentanyl Patch · DIN 09858348 · $3.3200 Teva-Fentanyl · DIN 09858349 · $3.3200
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09858350
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Duragesic 12 · DIN 02280345 · 12mcg/hr · Trans Patch

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.Discontinued 2009-11-24 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 511
Reason for Use code 511 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long-acting opioid will be subject to verification at the time of dispensing. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Duragesic 12 · DIN 02280345 Manufacturer: Janssen-Ortho Inc.; listing date 2008-12-23 Health Canada: Cancelled post market since 2009-11-24 · brand DURAGESIC 12 · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 12 MCG/HOUR · company Janssen inc · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Duragesic 12: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76602 · Verify on the e-Formulary ↗ (DIN 02280345)

Source record
DIN 02280345: Duragesic 12 Raw flags: notABenefit=Y, sec3=Y Item: 280808169; group id 402; item number 0961; lccId 00402; manufacturer id JNO Source form: Trans Patch; strength: 12mcg/hr Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02280345 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76602
Interchangeable products
Sandoz Fentanyl Patch · DIN 02327112 · $3.3200 Teva-Fentanyl · DIN 02311925 · $3.3200
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02280345
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.

Duragesic · DIN 02275813 · 25mcg/hr · Trans Patch

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.Discontinued 2018-10-31 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 511
Reason for Use code 511 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long-acting opioid will be subject to verification at the time of dispensing. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Duragesic · DIN 02275813 Manufacturer: Janssen Inc.; listing date 2010-04-23 Health Canada: Cancelled post market since 2018-10-31 · brand DURAGESIC · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 25 MCG/HOUR · company Janssen inc · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Duragesic: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76148 · Verify on the e-Formulary ↗ (DIN 02275813)

Source record
DIN 02275813: Duragesic Raw flags: notABenefit=Y, sec3=Y Item: 280808079; group id 404; item number 0963; lccId 00067; manufacturer id JAN Source form: Trans Patch; strength: 25mcg/hr Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02275813 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76148
Interchangeable products
Duragesic 25 · DIN 01937383 · not recorded Sandoz Fentanyl Patch · DIN 02327120 · $8.5600 Teva-Fentanyl · DIN 02282941 · $8.5600
Shortage status: discontinued (2018-11-01, reported by JANSSEN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02275813
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.

Duragesic 25 · DIN 01937383 · 25mcg/hr · Trans Patch

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.Discontinued 2009-11-24 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 511
Reason for Use code 511 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long-acting opioid will be subject to verification at the time of dispensing. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Duragesic 25 · DIN 01937383 Manufacturer: Janssen-Ortho Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2009-11-24 · brand DURAGESIC 25 · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 25 MCG/HOUR · company Janssen inc · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Duragesic 25: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12656 · Verify on the e-Formulary ↗ (DIN 01937383)

Source record
DIN 01937383: Duragesic 25 Raw flags: notABenefit=Y, sec3=Y Item: 280808079; group id 404; item number 0963; lccId 00067; manufacturer id JNO Source form: Trans Patch; strength: 25mcg/hr Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01937383 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12656
Interchangeable products
Duragesic · DIN 02275813 · not recorded Sandoz Fentanyl Patch · DIN 02327120 · $8.5600 Teva-Fentanyl · DIN 02282941 · $8.5600
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01937383
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.

Duragesic · DIN 02275821 · 50mcg/hr · Trans Patch

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.Discontinued 2018-10-31 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 511
Reason for Use code 511 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long-acting opioid will be subject to verification at the time of dispensing. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Duragesic · DIN 02275821 Manufacturer: Janssen Inc.; listing date 2010-04-23 Health Canada: Cancelled post market since 2018-10-31 · brand DURAGESIC · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 50 MCG/HOUR · company Janssen inc · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Duragesic: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76149 · Verify on the e-Formulary ↗ (DIN 02275821)

Source record
DIN 02275821: Duragesic Raw flags: notABenefit=Y, sec3=Y Item: 280808080; group id 404; item number 0964; lccId 00067; manufacturer id JAN Source form: Trans Patch; strength: 50mcg/hr Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02275821 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76149
Interchangeable products
Duragesic 50 · DIN 01937391 · not recorded Sandoz Fentanyl Patch · DIN 02327147 · $16.1100 Teva-Fentanyl · DIN 02282968 · $16.1100
Shortage status: discontinued (2018-11-01, reported by JANSSEN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02275821
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.

Duragesic 50 · DIN 01937391 · 50mcg/hr · Trans Patch

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.Discontinued 2009-11-24 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 511
Reason for Use code 511 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long-acting opioid will be subject to verification at the time of dispensing. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Duragesic 50 · DIN 01937391 Manufacturer: Janssen-Ortho Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2009-11-24 · brand DURAGESIC 50 · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 50 MCG/HOUR · company Janssen inc · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Duragesic 50: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12657 · Verify on the e-Formulary ↗ (DIN 01937391)

Source record
DIN 01937391: Duragesic 50 Raw flags: notABenefit=Y, sec3=Y Item: 280808080; group id 404; item number 0964; lccId 00067; manufacturer id JNO Source form: Trans Patch; strength: 50mcg/hr Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01937391 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12657
Interchangeable products
Duragesic · DIN 02275821 · not recorded Sandoz Fentanyl Patch · DIN 02327147 · $16.1100 Teva-Fentanyl · DIN 02282968 · $16.1100
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01937391
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.

Duragesic · DIN 02275848 · 75mcg/hr · Trans Patch

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.Discontinued 2018-10-31 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Duragesic · DIN 02275848 Manufacturer: Janssen Inc.; listing date 2010-04-23 Health Canada: Cancelled post market since 2018-10-31 · brand DURAGESIC · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 75 MCG/HOUR · company Janssen inc · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Duragesic: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76150 · Verify on the e-Formulary ↗ (DIN 02275848)

Source record
DIN 02275848: Duragesic Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280808081; group id 405; item number 0965; lccId None; manufacturer id JAN Source form: Trans Patch; strength: 75mcg/hr Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02275848 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76150
Interchangeable products
Duragesic 75 · DIN 01937405 · not recorded Sandoz Fentanyl Patch · DIN 02327155 · not recorded Teva-Fentanyl · DIN 02282976 · not recorded
Shortage status: discontinued (2018-11-01, reported by JANSSEN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02275848
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.

Duragesic 75 · DIN 01937405 · 75mcg/hr · Trans Patch

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.Discontinued 2009-11-24 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Duragesic 75 · DIN 01937405 Manufacturer: Janssen-Ortho Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2009-11-24 · brand DURAGESIC 75 · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 75 MCG/HOUR · company Janssen inc · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Duragesic 75: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12658 · Verify on the e-Formulary ↗ (DIN 01937405)

Source record
DIN 01937405: Duragesic 75 Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280808081; group id 405; item number 0965; lccId None; manufacturer id JNO Source form: Trans Patch; strength: 75mcg/hr Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01937405 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12658
Interchangeable products
Duragesic · DIN 02275848 · not recorded Sandoz Fentanyl Patch · DIN 02327155 · not recorded Teva-Fentanyl · DIN 02282976 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01937405
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.

Duragesic · DIN 02275856 · 100mcg/hr · Trans Patch

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.Discontinued 2018-10-31 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Duragesic · DIN 02275856 Manufacturer: Janssen Inc.; listing date 2010-04-23 Health Canada: Cancelled post market since 2018-10-31 · brand DURAGESIC · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 100 MCG/HOUR · company Janssen inc · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Duragesic: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76151 · Verify on the e-Formulary ↗ (DIN 02275856)

Source record
DIN 02275856: Duragesic Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280808082; group id 405; item number 0966; lccId None; manufacturer id JAN Source form: Trans Patch; strength: 100mcg/hr Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02275856 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76151
Interchangeable products
Duragesic 100 · DIN 01937413 · not recorded Sandoz Fentanyl Patch · DIN 02327163 · not recorded Teva-Fentanyl · DIN 02282984 · not recorded
Shortage status: discontinued (2018-11-01, reported by JANSSEN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02275856
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-10-31 — choose a marketed DIN from the same-category list.

Duragesic 100 · DIN 01937413 · 100mcg/hr · Trans Patch

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.Discontinued 2009-11-24 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Duragesic 100 · DIN 01937413 Manufacturer: Janssen-Ortho Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2009-11-24 · brand DURAGESIC 100 · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 100 MCG/HOUR · company Janssen inc · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Duragesic 100: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12659 · Verify on the e-Formulary ↗ (DIN 01937413)

Source record
DIN 01937413: Duragesic 100 Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280808082; group id 405; item number 0966; lccId None; manufacturer id JNO Source form: Trans Patch; strength: 100mcg/hr Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01937413 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12659
Interchangeable products
Duragesic · DIN 02275856 · not recorded Sandoz Fentanyl Patch · DIN 02327163 · not recorded Teva-Fentanyl · DIN 02282984 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01937413
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2009-11-24 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:08:08 Opiate Agonists) and how they are covered

Matched class: 28:08:08 Opiate Agonists

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE, ACETAMINOPHEN & CODEINE PHOSPHATE, CODEINE PHOSPHATE, HYDROMORPHONE HCL, METHADONE HCL, MORPHINE SULFATE, OXYCODONE HCL & ACETAMINOPHEN, OXYCODONE HCL & ACETYLSALICYLIC ACID 28:08:08 Opiate Agonists

ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 300mg & 15mg & 15mg, 300mg & 15mg & 30mg · Tab

ACETAMINOPHEN & CODEINE PHOSPHATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 160mg & 8mg/5mL, 300mg & 30mg, 300mg & 60mg · O/L, Tab

HYDROMORPHONE HCL

· 28 products · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) · strengths: 4.5mg, 9mg, 3mg, 6mg, 12mg, 18mg, 2mg/mL, 10mg/mL, 1mg/mL, 1mg, 2mg, 4mg, 8mg · CR Cap, Inj Sol-1mL Pk, Oral Sol, Tab

MORPHINE SULFATE

· 35 products · General benefit (31), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 10mg, 15mg, 30mg, 60mg, 100mg, 2mg/mL, 10mg/mL, 15mg/mL, 50mg/mL, 20mg, 50mg, 200mg, 5mg · ER Cap, Inj Sol Amp, Inj Sol-1mL Pk, SR Cap, SR Tab, Tab

OXYCODONE HCL & ACETAMINOPHEN

· 5 products · General benefit (4), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

OXYCODONE HCL & ACETYLSALICYLIC ACID

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE & CODEINE PHOSPHATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg & 15mg, 330mg & 50mg & 40mg & 30mg · Cap

OXYCODONE HCL

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg, 20mg · Tab

TRAMADOL HCL

· 13 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg, 300mg, 50mg · ER Tab, Tab

TRAMADOL HCL & ACETAMINOPHEN

· 11 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 37.5mg & 325mg · Tab

CODEINE PHOSPHATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 15mg, 30mg · Tab

METHADONE HCL

· 16 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg/mL, 1mg, 5mg, 10mg, 25mg · Oral Concentrate, Oral Concentrate (Cherry Flavour), Oral Concentrate (Unflavoured), Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:08 and 2 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults: TEVA-FENTANYL (fentanyl transdermal system) is indicated for the management of pain severe enough to require daily, continuous, long-term opioid treatment and:  that is opioid-responsive;  and for which alternative options are inadequate Only for use in patients who are already receiving opioid therapy at a total daily dose of at least 60 mg/day Morphine Equivalents. TEVA-FENTANYL is not indicated as an as-needed (prn) analgesic. The initial dose of TEVA-FENTANYL should be obtained or calculated from the conversion tables (see DOSAGE AND ADMINISTRATION), and must not be higher than that dose which is equivalent to the total dose of opioids the patient is receiving at the time of the switch to the patch. Because serious or life-threatening hypoventilation could occur, TEVA-FENTANYL should not TEVA-FENTANYL (12, 25, 50, 75 and 100 mcg/h) Page 3 of 60 be used in:  non-opioid-tolerant patients  the management of post-operative pain Pediatrics (< 18 years of age): The safety and efficacy of fentanyl transdermal system has not been studied in the pediatric population. Therefore, the… https://pdf.hres.ca/dpd_pm/00066268.PDF PM date: June 10, 2022 Source product: TEVA-FENTANYL; DIN 02282941; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Duragesic · DIN 02275813 Shortage status: discontinued (2018-11-01, reported by JANSSEN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02275813

Check this DIN again

Duragesic · DIN 02275821 Shortage status: discontinued (2018-11-01, reported by JANSSEN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02275821

Check this DIN again

Duragesic · DIN 02275848 Shortage status: discontinued (2018-11-01, reported by JANSSEN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02275848

Check this DIN again

Duragesic · DIN 02275856 Shortage status: discontinued (2018-11-01, reported by JANSSEN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02275856

Check this DIN again

Other review policies

For Sandoz Fentanyl Patch, Teva-Fentanyl, Duragesic 12, Duragesic, Duragesic 25, Duragesic 50, Duragesic 75, Duragesic 100: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026